Verve Therapeutics, Inc.
VERV
$6.16
-$0.16-2.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -181.01M | -198.71M | -197.03M | -192.65M | -196.83M |
| Total Depreciation and Amortization | 6.84M | 6.75M | 6.57M | 6.29M | 5.96M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.38M | 36.53M | 34.56M | 30.92M | 30.36M |
| Change in Net Operating Assets | -7.67M | -2.26M | -1.63M | 25.71M | 16.97M |
| Cash from Operations | -142.46M | -157.69M | -157.53M | -129.73M | -143.54M |
| Capital Expenditure | -4.53M | -3.74M | -4.53M | -4.66M | -6.34M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.87M | 78.61M | 40.97M | -27.55M | -22.99M |
| Cash from Investing | 68.34M | 74.88M | 36.44M | -32.21M | -29.33M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 26.48M | 49.26M | 201.89M | 233.80M | 233.72M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15.00K | -66.00K | -458.00K | -458.00K | -444.00K |
| Cash from Financing | 26.47M | 49.20M | 201.43M | 233.34M | 233.27M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -47.65M | -33.62M | 80.34M | 71.40M | 60.40M |